BR112017011411A2 - antagonistas da miostatina ou da activina para o tratamento da sarcopenia - Google Patents

antagonistas da miostatina ou da activina para o tratamento da sarcopenia

Info

Publication number
BR112017011411A2
BR112017011411A2 BR112017011411A BR112017011411A BR112017011411A2 BR 112017011411 A2 BR112017011411 A2 BR 112017011411A2 BR 112017011411 A BR112017011411 A BR 112017011411A BR 112017011411 A BR112017011411 A BR 112017011411A BR 112017011411 A2 BR112017011411 A2 BR 112017011411A2
Authority
BR
Brazil
Prior art keywords
sarcopenia
myostatin
treatment
activin
activin antagonists
Prior art date
Application number
BR112017011411A
Other languages
English (en)
Inventor
Rooks Daniel
Glass David
Papanicolaou Dimitris
Trifilieff Estelle
B Klickstein Lloyd
Kortebein Patrick
Roubenoff Ronenn
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55024187&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017011411(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112017011411A2 publication Critical patent/BR112017011411A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Abstract

a presente invenção refere-se a antagonistas da miostatina ou da activina, a um regime de dose e a composições farmacêuticas dos mesmos, para o tratamento da sarcopenia, em particular da sarcopenia relacionada com a idade. em especial, o antagonista da miostatina ou da activina bimagrumab foi considerado benéfico no tratamento de adultos idosos com sarcopenia com respeito ao aumento de sua força e função dos músculos esqueléticos.
BR112017011411A 2014-12-08 2015-12-04 antagonistas da miostatina ou da activina para o tratamento da sarcopenia BR112017011411A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462088802P 2014-12-08 2014-12-08
PCT/IB2015/059369 WO2016092439A1 (en) 2014-12-08 2015-12-04 Myostatin or activin antagonists for the treatment of sarcopenia

Publications (1)

Publication Number Publication Date
BR112017011411A2 true BR112017011411A2 (pt) 2018-02-14

Family

ID=55024187

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017011411A BR112017011411A2 (pt) 2014-12-08 2015-12-04 antagonistas da miostatina ou da activina para o tratamento da sarcopenia

Country Status (17)

Country Link
US (1) US20170260275A1 (pt)
EP (1) EP3229907A1 (pt)
JP (1) JP2017538701A (pt)
KR (1) KR20170094292A (pt)
CN (1) CN106999589A (pt)
AU (2) AU2015358939A1 (pt)
BR (1) BR112017011411A2 (pt)
CA (1) CA2969800A1 (pt)
CL (1) CL2017001438A1 (pt)
IL (1) IL252507A0 (pt)
MX (1) MX2017007519A (pt)
PH (1) PH12017500965A1 (pt)
RU (1) RU2017123880A (pt)
SG (1) SG11201704094QA (pt)
TN (1) TN2017000217A1 (pt)
TW (1) TW201627007A (pt)
WO (1) WO2016092439A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2568436T3 (es) 2006-03-31 2016-04-29 Chugai Seiyaku Kabushiki Kaisha Procedimiento para controlar la farmacocinética en sangre de anticuerpos
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
EP4238993A3 (en) 2008-04-11 2023-11-29 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
SG190727A1 (en) 2010-11-30 2013-07-31 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
TWI697501B (zh) 2012-08-24 2020-07-01 日商中外製藥股份有限公司 ＦｃγＲＩＩｂ特異性Ｆｃ區域變異體
WO2014163101A1 (ja) 2013-04-02 2014-10-09 中外製薬株式会社 Ｆｃ領域改変体
TWI808330B (zh) 2014-12-19 2023-07-11 日商中外製藥股份有限公司 抗肌抑素之抗體、含變異Fc區域之多胜肽及使用方法
TW202248212A (zh) 2015-02-05 2022-12-16 日商中外製藥股份有限公司 包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHODS OF USE
JP6987072B2 (ja) 2016-03-10 2021-12-22 アクセレロン ファーマ インコーポレーテッド アクチビン２型受容体結合タンパク質及びその使用
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATING TO IL-8
US10485502B2 (en) * 2016-12-20 2019-11-26 General Electric Company System and method for assessing muscle function of a patient
JOP20190152A1 (ar) * 2016-12-21 2019-06-20 Novartis Ag مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة
KR101917794B1 (ko) 2018-05-10 2018-11-13 한국과학기술원 진세노사이드 Rh2를 포함하는 근육 질환 개선, 예방 또는 치료용 조성물
KR101966117B1 (ko) 2018-05-25 2019-04-05 (주)녹십자웰빙 가공인삼추출물을 포함하는 근육 분화 촉진용 조성물
KR102017282B1 (ko) 2019-01-28 2019-09-02 (주)녹십자웰빙 가공인삼추출물을 포함하는 근육 분화 촉진용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1968621A2 (en) * 2005-12-06 2008-09-17 Amgen Inc. Uses of myostatin antagonists
US20070190056A1 (en) * 2006-02-07 2007-08-16 Ravi Kambadur Muscle regeneration compositions and uses therefor
TW201907946A (zh) * 2007-02-02 2019-03-01 美商艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TWI573802B (zh) * 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
SI2424895T1 (en) 2009-04-27 2018-01-31 Novartis Ag Ingredients and procedures for increasing muscle growth
AR081556A1 (es) * 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
HUE040276T2 (hu) * 2011-07-01 2019-02-28 Novartis Ag Eljárás metabolikus rendellenességek kezelésére
JP2015525230A (ja) * 2012-06-11 2015-09-03 アムジエン・インコーポレーテツド デュアル受容体アンタゴニスト性抗原結合タンパク質およびその使用
RU2016108652A (ru) * 2013-08-14 2017-09-14 Новартис Аг Способы лечения спорадического миозита с тельцами включений
TW201622746A (zh) * 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法

Also Published As

Publication number Publication date
US20170260275A1 (en) 2017-09-14
AU2015358939A1 (en) 2017-06-15
AU2019200082A1 (en) 2019-01-31
CN106999589A (zh) 2017-08-01
KR20170094292A (ko) 2017-08-17
TN2017000217A1 (en) 2018-10-19
RU2017123880A3 (pt) 2019-08-29
CL2017001438A1 (es) 2018-02-16
TW201627007A (zh) 2016-08-01
SG11201704094QA (en) 2017-06-29
JP2017538701A (ja) 2017-12-28
PH12017500965A1 (en) 2017-10-18
CA2969800A1 (en) 2016-06-16
EP3229907A1 (en) 2017-10-18
MX2017007519A (es) 2017-08-22
IL252507A0 (en) 2017-07-31
WO2016092439A1 (en) 2016-06-16
RU2017123880A (ru) 2019-01-10

Similar Documents

Publication Publication Date Title
BR112017011411A2 (pt) antagonistas da miostatina ou da activina para o tratamento da sarcopenia
EA201791702A1 (ru) Терапевтические средства на основе гликанов и связанные с ними способы
MA52257A (fr) Compositions pharmaceutiques comprenant blautia et leur administration orale
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
BR112016022062A2 (pt) Combinação, composição farmacêutica, uso de uma combinação ou de uma composição farmacêutica, e, produto farmacêutico
BR112017007072A2 (pt) compostos de triazolopiridina e métodos para o tratamento de fibrose cística
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
BR112017014994A2 (pt) formulação em pó nasal para o tratamento de hipoglicemia
MX2016014581A (es) Composiciones de compuestos que modulan nmdar.
IL265970B (en) Sulfoxyalkyl organonitro compounds and related compounds and pharmaceutical preparations for use in medicine
CO2017001658A2 (es) Compuestos tricíclicos que contienen nitrógeno para el tratamiento de la infección por neisseria gonorrhoeae
DOP2016000212A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
BR112017006005A2 (pt) composição farmacêutica, e, método de prevenção ou tratamento de uma infecção por hiv.
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
CO2017001601A2 (es) Derivados de 1-acetil-4-((pirazin-2-il) amino)-1,2,3,4-tetrahydroquinolina-6 carboxamida como inhibidores de bromodominio
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA201692020A1 (ru) Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях
BR112017024163A2 (pt) compostos bicíclicos
TR201908639T4 (tr) Dejeneratif göz bozukluklarının önlenmesi ve veya tedavisine yönelik safran bazlı bileşimler.
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
BR112015024703A2 (pt) formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose
BR112017027285A2 (pt) ?cocristal, composição farmacêutica e método para o tratamento de uma doença?
BR112017007364A2 (pt) composição farmacêutica para o uso no tratamento ou prevenção de deficiências de vitaminas e minerais em pacientes que foram submetidos à cirurgia de bypass gástrico

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements